AnaptysBio’s (ANAB) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of AnaptysBio (NASDAQ:ANAB) in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a $22.00 target price on the biotechnology company’s stock.

ANAB has been the subject of several other research reports. BTIG Research lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. dropped their target price on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a report on Thursday, December 19th. Wedbush restated an “outperform” rating and set a $40.00 target price on shares of AnaptysBio in a research report on Wednesday, February 12th. Wells Fargo & Company upped their price target on AnaptysBio from $40.00 to $51.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. Finally, Guggenheim dropped their price objective on AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $35.11.

AnaptysBio Trading Down 2.1 %

Shares of NASDAQ:ANAB opened at $16.40 on Tuesday. The firm has a market capitalization of $499.04 million and a PE ratio of -2.70. AnaptysBio has a 1-year low of $12.21 and a 1-year high of $41.31. The business’s 50 day moving average is $16.16 and its 200-day moving average is $24.22.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.61) by $0.89. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $43.11 million for the quarter, compared to the consensus estimate of $10.17 million. On average, sell-side analysts predict that AnaptysBio will post -6.08 EPS for the current year.

Insiders Place Their Bets

In related news, Director Ecor1 Capital, Llc bought 6,646 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was bought at an average cost of $12.95 per share, with a total value of $86,065.70. Following the completion of the purchase, the director now owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. The trade was a 0.08 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 33.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC raised its position in shares of AnaptysBio by 131.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 1,531 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in AnaptysBio in the fourth quarter valued at about $40,000. AlphaQuest LLC increased its position in AnaptysBio by 1,891.5% in the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 4,237 shares during the period. Virtus ETF Advisers LLC raised its holdings in AnaptysBio by 24.7% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 936 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in AnaptysBio by 1,585.8% during the 4th quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 5,360 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.